The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis

E. McAlister; M. Kirkby; J. Domínguez-Robles; A.J. Paredes; Q.K. Anjani; K. Moffatt; L.K. Vora; Aaron R.J. Hutton; P.E. McKenna; E. Larrañeta; R.F. Donnelly

doi:10.1016/j.addr.2021.06.002

The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis

E. McAlister, M. Kirkby, J. Domínguez-Robles, A.J. Paredes, Q.K. Anjani, K. Moffatt, L.K. Vora, Aaron R.J. Hutton, P.E. McKenna, E. Larrañeta, R.F. Donnelly

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

Abstract

Diabetes affects approximately 450 million adults globally. If not effectively managed, chronic hyperglycaemia causes tissue damage that can develop into fibrosis. Fibrosis leads to end-organ complications,
failure of organ systems occurs, which can ultimately cause death. One strategy to tackle end-organ complications is to maintain normoglycaemia. Conventionally, insulin is administered subcutaneously.
Whilst effective, this delivery route shows several limitations, including pain. The transdermal route is
a favourable alternative. Microneedle (MN) arrays are minimally invasive and painless devices that can
enhance transdermal drug delivery. Convincing evidence is provided on MN-mediated insulin delivery.
MN arrays can also be used as a diagnostic tool and monitor glucose levels. Furthermore, sophisticated
MN array-based systems that integrate glucose monitoring and drug delivery into a single device have
been designed. Therefore, MN technology has potential to revolutionise diabetes management. This
review describes the current applications of MN technology for diabetes management and how these
could prevent diabetes induced fibrosis.

Original language	English
Article number	113825
Pages (from-to)	1-29
Number of pages	29
Journal	Advanced drug delivery reviews
Volume	175
Early online date	7 Jun 2021
DOIs	https://doi.org/10.1016/j.addr.2021.06.002
Publication status	Published (in print/issue) - 31 Aug 2021

Keywords

Diabetes
End-organ complications
Microneedle-mediated transdermal delivery
Minimally invasive devices
Insulin delivery systems
Glucose monitoring
Interstitial fludi

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.addr.2021.06.002

Cite this

McAlister, E., Kirkby, M., Domínguez-Robles, J., Paredes, A. J., Anjani, Q. K., Moffatt, K., Vora, L. K., Hutton, A. R. J., McKenna, P. E., Larrañeta, E., & Donnelly, R. F. (2021). The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis. Advanced drug delivery reviews, 175, 1-29. Article 113825. https://doi.org/10.1016/j.addr.2021.06.002

@article{1d7cf7ba5caa46b38e902c9e7d1a2ada,

title = "The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis",

abstract = "Diabetes affects approximately 450 million adults globally. If not effectively managed, chronic hyperglycaemia causes tissue damage that can develop into fibrosis. Fibrosis leads to end-organ complications,failure of organ systems occurs, which can ultimately cause death. One strategy to tackle end-organ complications is to maintain normoglycaemia. Conventionally, insulin is administered subcutaneously.Whilst effective, this delivery route shows several limitations, including pain. The transdermal route isa favourable alternative. Microneedle (MN) arrays are minimally invasive and painless devices that canenhance transdermal drug delivery. Convincing evidence is provided on MN-mediated insulin delivery.MN arrays can also be used as a diagnostic tool and monitor glucose levels. Furthermore, sophisticatedMN array-based systems that integrate glucose monitoring and drug delivery into a single device havebeen designed. Therefore, MN technology has potential to revolutionise diabetes management. Thisreview describes the current applications of MN technology for diabetes management and how thesecould prevent diabetes induced fibrosis.",

keywords = "Diabetes, End-organ complications, Microneedle-mediated transdermal delivery, Minimally invasive devices, Insulin delivery systems, Glucose monitoring, Interstitial fludi",

author = "E. McAlister and M. Kirkby and J. Dom{\'i}nguez-Robles and A.J. Paredes and Q.K. Anjani and K. Moffatt and L.K. Vora and Hutton, {Aaron R.J.} and P.E. McKenna and E. Larra{\~n}eta and R.F. Donnelly",

year = "2021",

month = aug,

day = "31",

doi = "10.1016/j.addr.2021.06.002",

language = "English",

volume = "175",

pages = "1--29",

journal = "Advanced drug delivery reviews",

issn = "0169-409X",

publisher = "Elsevier",

}

TY - JOUR

T1 - The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis

AU - McAlister, E.

AU - Kirkby, M.

AU - Domínguez-Robles, J.

AU - Paredes, A.J.

AU - Anjani, Q.K.

AU - Moffatt, K.

AU - Vora, L.K.

AU - Hutton, Aaron R.J.

AU - McKenna, P.E.

AU - Larrañeta, E.

AU - Donnelly, R.F.

PY - 2021/8/31

Y1 - 2021/8/31

N2 - Diabetes affects approximately 450 million adults globally. If not effectively managed, chronic hyperglycaemia causes tissue damage that can develop into fibrosis. Fibrosis leads to end-organ complications,failure of organ systems occurs, which can ultimately cause death. One strategy to tackle end-organ complications is to maintain normoglycaemia. Conventionally, insulin is administered subcutaneously.Whilst effective, this delivery route shows several limitations, including pain. The transdermal route isa favourable alternative. Microneedle (MN) arrays are minimally invasive and painless devices that canenhance transdermal drug delivery. Convincing evidence is provided on MN-mediated insulin delivery.MN arrays can also be used as a diagnostic tool and monitor glucose levels. Furthermore, sophisticatedMN array-based systems that integrate glucose monitoring and drug delivery into a single device havebeen designed. Therefore, MN technology has potential to revolutionise diabetes management. Thisreview describes the current applications of MN technology for diabetes management and how thesecould prevent diabetes induced fibrosis.

AB - Diabetes affects approximately 450 million adults globally. If not effectively managed, chronic hyperglycaemia causes tissue damage that can develop into fibrosis. Fibrosis leads to end-organ complications,failure of organ systems occurs, which can ultimately cause death. One strategy to tackle end-organ complications is to maintain normoglycaemia. Conventionally, insulin is administered subcutaneously.Whilst effective, this delivery route shows several limitations, including pain. The transdermal route isa favourable alternative. Microneedle (MN) arrays are minimally invasive and painless devices that canenhance transdermal drug delivery. Convincing evidence is provided on MN-mediated insulin delivery.MN arrays can also be used as a diagnostic tool and monitor glucose levels. Furthermore, sophisticatedMN array-based systems that integrate glucose monitoring and drug delivery into a single device havebeen designed. Therefore, MN technology has potential to revolutionise diabetes management. Thisreview describes the current applications of MN technology for diabetes management and how thesecould prevent diabetes induced fibrosis.

KW - Diabetes

KW - End-organ complications

KW - Microneedle-mediated transdermal delivery

KW - Minimally invasive devices

KW - Insulin delivery systems

KW - Glucose monitoring

KW - Interstitial fludi

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85108018456&partnerID=MN8TOARS

U2 - 10.1016/j.addr.2021.06.002

DO - 10.1016/j.addr.2021.06.002

M3 - Article

SN - 0169-409X

VL - 175

SP - 1

EP - 29

JO - Advanced drug delivery reviews

JF - Advanced drug delivery reviews

M1 - 113825

ER -

The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this